%0 Journal Article %A Adel S. Alharbi %A Mohamed Alzahrani %A Abdulrahman N. Alodayani %A Mohamed Y. Alhindi %A Saleh Alharbi %A Abdulrahman Alnemri %T Saudi experts’ recommendation for RSV prophylaxis in the era of COVID-19 %B Consensus from the Saudi Pediatric Pulmonology Association %D 2021 %R 10.15537/smj.2021.42.4.20200769 %J Saudi Medical Journal %P 355-362 %V 42 %N 4 %X Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and viral pneumonia in pediatrics worldwide. In the Kingdom of Saudi Arabia (KSA), the prevalence of RSV is 23.5% in pediatric patients with acute lower respiratory tract illness. Coronavirus disease (COVID-19) poses critical public health and socioeconomic challenges in KSA. The Saudi Pediatric Pulmonology Association (SPPA), a subsidiary of the Saudi Thoracic Society (STS), developed a task force to determine the potential challenges and barriers to the RSV immunoprophylaxis program during the era of COVID-19 and to compose a practical, nationwide, and multidisciplinary approach to address these challenges. Some of the recommendations to manage these challenges include increasing the number of RSV immunoprophylaxis clinics, drive-thru visits, home-care services, and swift referrals to the RSV immunoprophylaxis program specialists. Additional training is required for healthcare personnel to add RSV immunoprophylaxis to the regular immunization schedule. %U https://smj.org.sa/content/smj/42/4/355.full.pdf